Home
Products
Products Overview
Products Pipeline
Iluvien Overview
Iluvien Professional Resources
Diabetic Eye Disease
Overview
Vision Loss
Progression
Prevalence
Treatments
Investor Relations
Strategic Partners
News
About
Corporate Overview
Management Team
Board of Directors
Careers
Contact
Investors
Alimera Sciences is a private venture backed specialty pharmaceutical company having been founded in June 2003. Alimera's financing partners represent the top tier of biotech venture companies, who are among the most established and well financed in their fields.
Alimera has had three rounds of financing to date. A Series A financing was completed in July 2004 and raised $26.75 million from Intersouth Partners, Domain Associates, Polaris Partners and Scale Venture Partners. A Series B financing of $31.8 million was completed in November 2005 and included the existing investors along with Venrock Associates. A Series C financing of $30 million was completed in March 2008 with all five investors exercising their right to participate at their full pro rata share. In August of 2009, Alimera closed a $5 million extension of its Series C financing. In connection with this financing, the purchasers received warrants for an additional $10 million in Series C preferred stock which were exercised in December 2009 after successful topline results from the Phase III FAME Study.
"Alimera's financing partners represent the top tier of biotech venture companies, who are among the most established and well financed in their fields."
Home
Products
Diabetic Eye Disease
Investor Relations
News
About
Contact
Copyright 2008 Alimera Sciences. All Rights Reserved.
Read our site
Legal Statement
and
Privacy Policy